Key Drivers
- Strong Cash Flow
- Elevated Debt Load
- Modest Profitability
AIAI Summary
GRFS is an execution-and-deleveraging investment, not simply a cheap plasma-stock trade: upside depends on sustaining €500–575M in annual free cash flow and applying it to debt reduction, while weak revenue growth and heavy interest costs remain the key risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Elevated Debt Load
- •Modest Profitability
GRFS offers cash-backed profitability and reasonable valuation, but high leverage and heavy interest costs make deleveraging the key investment risk.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Selling pressure
GRFS remains bearish over the last month, with $7.30–$7.36 support critical; a break below $7.30 signals further downside, while reclaiming $7.40–$7.55 is needed to stabilize.
Repeated rejection near $7.55 indicates persistent selling pressure
Sentiment & News
Key News Insights:
- •Plasma sourcing
- •Cash conversion
- •Valuation discount
Grifols' investment case hinges on operational execution and cash conversion, with its 30%+ valuation discount offering upside only if plasma sourcing and network productivity improve.
Operational progress could narrow Grifols' peer discount, while weak execution may keep valuation pressured
Similar Companies in Healthcare
Other companies in the same sector with AI ratings